ICLR250117P200000
- 6.50
- 0.000.00%
Icon PLC Newsroom
ICON Plc Released The Findings Of A Survey Of Over 120 Biotech And Pharma Professionals Developing Treatments For Neurodegenerative Disorders
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer's and Related Disorders ICON Survey
ICON Plc Draws Bullish Views at RBC on Attractive Valuation
Icon Shares Are Trading Higher After RBC Capital Initiated Coverage on the Stock With an Outperform Rating and Announced a Price Target of $263.
ICON Up Over 5%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Icon Price Target Announced at $263.00/Share by RBC Capital
Icon Initiated at Outperform by RBC Capital
ICON Plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference
RBC Capital Initiates Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $263
Icon Price Target Cut to $290.00/Share From $300.00 by Citigroup
Icon Is Maintained at Buy by Citigroup
Citi Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $290
Does ICON (NASDAQ:ICLR) Have A Healthy Balance Sheet?
ICON Public Limited Company (ICLR) Slid on Drop in Biotechnology Funding
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $260
ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research
Icon Analyst Ratings
Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $284